1. Home
  2. SLXN vs AMBO Comparison

SLXN vs AMBO Comparison

Compare SLXN & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • AMBO
  • Stock Information
  • Founded
  • SLXN 2008
  • AMBO 2000
  • Country
  • SLXN Israel
  • AMBO United States
  • Employees
  • SLXN N/A
  • AMBO N/A
  • Industry
  • SLXN
  • AMBO Other Consumer Services
  • Sector
  • SLXN
  • AMBO Real Estate
  • Exchange
  • SLXN NYSE
  • AMBO Nasdaq
  • Market Cap
  • SLXN 7.3M
  • AMBO 7.0M
  • IPO Year
  • SLXN N/A
  • AMBO 2010
  • Fundamental
  • Price
  • SLXN $0.83
  • AMBO $2.80
  • Analyst Decision
  • SLXN Strong Buy
  • AMBO
  • Analyst Count
  • SLXN 1
  • AMBO 0
  • Target Price
  • SLXN $5.00
  • AMBO N/A
  • AVG Volume (30 Days)
  • SLXN 784.5K
  • AMBO 13.0K
  • Earning Date
  • SLXN 08-21-2025
  • AMBO 01-01-0001
  • Dividend Yield
  • SLXN N/A
  • AMBO N/A
  • EPS Growth
  • SLXN N/A
  • AMBO N/A
  • EPS
  • SLXN N/A
  • AMBO 0.11
  • Revenue
  • SLXN N/A
  • AMBO $9,392,000.00
  • Revenue This Year
  • SLXN N/A
  • AMBO N/A
  • Revenue Next Year
  • SLXN N/A
  • AMBO N/A
  • P/E Ratio
  • SLXN N/A
  • AMBO $25.19
  • Revenue Growth
  • SLXN N/A
  • AMBO 2.50
  • 52 Week Low
  • SLXN $0.58
  • AMBO $1.00
  • 52 Week High
  • SLXN $41.85
  • AMBO $5.55
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • AMBO 53.46
  • Support Level
  • SLXN N/A
  • AMBO $2.63
  • Resistance Level
  • SLXN N/A
  • AMBO $3.00
  • Average True Range (ATR)
  • SLXN 0.00
  • AMBO 0.30
  • MACD
  • SLXN 0.00
  • AMBO 0.03
  • Stochastic Oscillator
  • SLXN 0.00
  • AMBO 55.00

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

Share on Social Networks: